33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • MOUNTAINEER: Open-label, phase 2 study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress)
    Meeting Abstract

    Siena, S.; Elez, E.; Peeters, M.; AndreĢ, T.; Van den Eynde, M.; Ng, K.; Cercek, A.; Fountzilas, C.; Sanchez, F.; Hubbard, J.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy compared with chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015
    Meeting Abstract

    Tabernero, J.; Cohen, D.; Van Cutsem, E.; Janjigian, Y.; Bang, Y.; Qin, S.; Wang, A.; Hawk, N.; Shih, C.; Bhagia, P.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in progress
    Meeting Abstract

    Strickler, J.; Nakamura, Y.; Shitara, K.; Catenacci, D.; Janjigian, Y.; Barzi, A.; Bekaii-Saab, T.; Lenz, H.; Lee, J.; Van Cutsem, E.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Progression-free survival in patients with cholangiocarcinoma with FGFR2 fusions or rearrangements: A FIGHT-202 post-hoc analysis of prior systemic therapy response
    Meeting Abstract

    Abou-Alfa, G.; Sahai, V.; Hollebecque, A.; Vaccaro, G.; Melisi, D.; Al-Rajabi, R.; Paulson, A.; Borad, M.; Gallinson, D.; Murphy, A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • MATTERHORN: A phase 3 study of efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer
    Meeting Abstract

    Janjigian, Y.; Van Cutsem, E.; Muro, K.; Wainberg, Z.; Al-Batran, S.; Hyung, W.; Molena, D.; Evans, B.; Ruscica, D.; Robbins, S.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Dermatopathological review of cutaneous squamous cell carcinoma events in patients with gastrointestinal stromal tumors treated with ripretinib
    Meeting Abstract

    Patel, A.; George, S.; Janku, F.; Ganjoo, K.; Young, R.; Chi, P.; Westwood, D.; Stearns, S.; Meade, J.; Ruiz-Soto, R.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors
    Meeting Abstract

    Goyal, L.; Subbiah, V.; Mahipal, A.; Kamath, S.; Mody, K.; Borad, M.; El-Khoueiry, A.; Sahai, V.; Kim, R.; Kelley, R.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • KRYSTAL-10: A randomized phase 3 study of adagrasib (MRTX849) in combination with cetuximab vs chemotherapy in patients with previously treated advanced colorectal cancer with KRASG12C mutation
    Meeting Abstract

    Tabernero, J.; Bendell, J.; Corcoran, R.; Kopetz, S.; Lee, J.; Davis, M.; Christensen, J.; Chi, A.; Kheoh, T.; Yaeger, R.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Constructing hybrid control for the Morpheus metastatic colorectal cancer trial using IMblaze370 historical trial data
    Meeting Abstract

    Li, C.; Ferro, A.; Mhatre, S.; Lu, D.; Lawrance, M.; Li, S.; Allen, S.; Desai, J.; Fakih, M.; Kim, T.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Experience of infection preventionists during the first wave of COVID-19 outside of China
    Meeting Abstract

    Bubb, T. N.; Haas, J. P.
    American Journal of Infection Control (2021)

    Fulltext@MSK | Save